Communicable Diseases, Emerging: Clinical Trials

17 trials for Communicable Diseases, Emerging, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 recruiting, 5 completed, 2 unknown, 1 enrolling by invitation. 4 Phase 2, 2 Not applicable, 2 Phase 3, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 24Completed 1, Recruiting 1, Suspended 1, Terminated 1
Not applicable2Enrolling by invitation 1, Recruiting 1
Phase 32Recruiting 1, Terminated 1
Phase 41Recruiting 1

Follow Communicable Diseases, Emerging: new trials by email Literature Review of Communicable Diseases, Emerging trials Research Report on Communicable Diseases, Emerging

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
BRAVO is a Phased Outbreak-response Study in the DRC Evaluating ERVEBO® Vaccination in ~20,000 Frontline Workers During the 2026 BDV Outbreak, Step A Assesses Real-world Effectiveness, Safety, and Impact on Severe Disease and Mortality, While Generating Evidence for Future BDV Vaccination Strategies
ERVEBO Vaccination - Ebola, Bundibugyo Virus Disease (BVD)
Phase 4RecruitingEpicentre200002026-09-192026-10-29
Smart Analysis and Decision-Making for Emerging Infectious Diseases
Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices - Emerging Infectious Diseases, COVID-19
Not applicableEnrolling by invitationPeking University1082026-08-102026-08-19
Biological Collection on Emerging Infectious Diseases and Their Treatments
Emerging Infectious Diseases and Their Treatments
Not yet recruitingUniversity Hospital, Toulouse53002026-06-152026-06-29
Post-Emergency Optimization of Antibiotic Therapy for Urinary Tract Infection (UTI)
Adaptation of antibiotics therapy for outpatient urinary infection following emergency care - Urinary Tract Infections, Antiobiotic Stewardship
RecruitingCentre Hospitalier Intercommunal Creteil3302026-06-012026-08-26
ARN-75039 Lassa Fever Treatment in West Africa
ARN-75039 high, Intravenous ribavirin, ARN-75039 low - Lassa Fever
Phase 2SuspendedArisan Therapeutics, Inc.1352026-02-142026-07-06
Development of a Rapid Diagnostic Test to Identify Crimean-Congo Hemorrhagic Fever - Research and Development Testing
Infectious Diseases, Emerging
CompletedLiverpool School of Tropical Medicine1962025-06-172026-08-27
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Favipiravir, Ribavirin, Dexamethasone - Lassa Fever
Phase 2 / Phase 3RecruitingIrrua Specialist Teaching Hospital17552025-05-022026-02-04
RVF and Other Emerging Infectious Diseases in East and Central Africa
Evidence of past or recent RVF exposure - Rift Valley Fever, Hemorrhagic Fevers, Viral
RecruitingWashington State University50002025-02-012026-10-05
Rapid Molecular Diagnosis and Detection of Emerging Infectious Diseases in Patients With Tropical Fever (Tropifever)
Diagnosis algorithm according to the delay between travel and consultation - Infectious Diseases in Febrile Patients Returning From Tropical Countries
Not applicableRecruitingAssistance Publique - Hôpitaux de Paris5642024-08-262025-06-06
Establishment of a Biobank for the Evaluation of Rapid Diagnostic Solutions
Emerging Infectious Diseases, Communicable Diseases
RecruitingAssistance Publique - Hôpitaux de Paris8002024-06-032026-02-17
Collaborative Open Research Initiative Study (CORIS-1)
No intervention. This is an observational study - Patient Engagement, COVID-19
UnknownChisquares Incorporated150002024-06-012024-04-10
Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III
Ebola Virus Disease
CompletedNational Institute of Allergy and Infectious Diseases (NIAID)2032022-08-252025-07-18
EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial
Baricitinib, Placebo - COVID-19, Emerging Infectious Disease
Phase 2 / Phase 3TerminatedOslo University Hospital2902021-06-032023-02-06
Epidemiology and Clinical Characteristics of Emerging and Re-emerging Infectious Diseases With Epidemic Potential in Mali
Observational Study - Febrile Illness
UnknownUniversity Clinical Research Center, Mali4002020-06-182022-07-01
Acceptability of Telehealth Triage Using Robotic Systems in COVID-19
Doctor Spot - COVID-19, Telemedicine
CompletedBrigham and Women's Hospital402020-03-102022-09-21
Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases
Plasma - Communicable Diseases, Communicable Diseases, Emerging
CompletedNational Institute of Allergy and Infectious Diseases (NIAID)102015-03-042025-05-16
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
Anti-Influenza Immune Plasma, Standard Care - Influenza A, Influenza B
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)982010-12-012017-09-05

Narrower conditions

COVID-19 (4)  ·  Hemorrhagic Fevers, Viral (4)  ·  Communicable Diseases (3)  ·  Hemorrhagic Fever, Ebola (2)  ·  Lassa Fever (2)  ·  Burnout, Professional (1)  ·  Chikungunya Fever (1)  ·  Dengue (1)  ·  Emergencies (1)  ·  Infections (1)  ·  Influenza in Birds (1)  ·  Influenza, Human (1)  ·  Mpox, Monkeypox (1)  ·  Neglected Diseases (1)

Broader conditions

Disease Attributes (17)  ·  Pathologic Processes (17)  ·  Pathological Conditions, Signs and Symptoms (17)  ·  Infections (16)  ·  Communicable Diseases (14)  ·  RNA Virus Infections (10)  ·  Virus Diseases (10)  ·  Coronaviridae Infections (4)  ·  Coronavirus Infections (4)  ·  Lung Diseases (4)  ·  Nidovirales Infections (4)  ·  Pneumonia (4)  ·  Pneumonia, Viral (4)  ·  Respiratory Tract Diseases (4)  ·  Respiratory Tract Infections (4)

Interventions

Standard of Care (2)  ·  Dexamethasone (1)  ·  Immunoglobulin M (1)  ·  Observation (1)  ·  Ribavirin (1)  ·  baricitinib (1)  ·  favipiravir (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Arisan Therapeutics, Inc. (1)  ·  Brigham and Women's Hospital (1)  ·  Centre Hospitalier Intercommunal Creteil (1)  ·  Chisquares Incorporated (1)  ·  Epicentre (1)  ·  Irrua Specialist Teaching Hospital (1)  ·  Liverpool School of Tropical Medicine (1)  ·  Oslo University Hospital (1)  ·  Peking University (1)  ·  University Clinical Research Center, Mali (1)  ·  University Hospital, Toulouse (1)  ·  Washington State University (1)

Countries

France (5)  ·  United States (4)  ·  Democratic Republic of the Congo (2)  ·  Liberia (2)  ·  Nigeria (2)  ·  Turkey (Türkiye) (2)  ·  Austria (1)  ·  Belgium (1)  ·  China (1)  ·  Czechia (1)  ·  Germany (1)  ·  Greece (1)  ·  Hungary (1)  ·  Ireland (1)  ·  Italy (1)

Top investigators

Ana Cubas Isabel Atienzar, PhD (1)  ·  Bridgette J Billioux, M.D. (1)  ·  Domique Costagliola, PhD (1)  ·  John Beigel, MD (1)  ·  Jose R Arribas, MD PhD (1)  ·  Jue Liu, Doctor (1)  ·  Ken McCormack, PhD (1)  ·  M. Kariuki Njenga, PhD (1)  ·  Richard Davey, MD (1)  ·  Richard T Davey, M.D. (1)

Results publications

PMID 28522352, PMID 33662134, PMID 34473343, PMID 35571871, PMID 36627655, PMID 41652539

NIH funding

U01AI151799 (1)